Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Galderma

< Previous 1 2 Next >
News headline image
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
From Galderma
Via Business Wire
News headline image
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
From Galderma
Via Business Wire
News headline image
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
From Galderma
Via Business Wire
News headline image
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance
From Galderma
Via Business Wire
News headline image
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
From Galderma
Via Business Wire
News headline image
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
From Galderma
Via Business Wire
News headline image
Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
From Galderma
Via Business Wire
News headline image
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
From Galderma
Via Business Wire
News headline image
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
From Galderma
Via Business Wire
News headline image
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
From Galderma
Via Business Wire
News headline image
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
From Galderma
Via Business Wire
News headline image
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
From Galderma
Via Business Wire
News headline image
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
From Galderma
Via Business Wire
News headline image
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
From Galderma
Via Business Wire
News headline image
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
From Galderma
Via Business Wire
News headline image
IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position
From Galderma
Via Business Wire
News headline image
Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
From Galderma
Via Business Wire
News headline image
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
From Galderma
Via Business Wire
News headline image
Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines
From Galderma
Via Business Wire
News headline image
Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories
From Galderma
Via Business Wire
News headline image
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
From Galderma
Via Business Wire
News headline image
Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis
From Galderma
Via Business Wire
News headline image
EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
From Galderma
Via Business Wire
News headline image
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
From Galderma
Via Business Wire
News headline image
Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology
From Galderma
Via Business Wire
News headline image
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4
From Galderma
Via Business Wire
News headline image
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology
From Galderma
Via Business Wire
News headline image
Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round
From Galderma
Via Business Wire
News headline image
Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables
From Galderma
Via Business Wire
News headline image
AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio
From Galderma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.